To assess the variety of isoforms identified by the four selected anti-CD44 mAbs, western blots were performed with lysates of the three tumorigenic cell lines (MB-231, breast cancer; HTB-66, melanoma; U87, glioblastoma). This evidence concerns the gene CD44 and breast carcinoma.